The week in pharma: action, reaction and insight – week to December 13

15 December 2024

By Barbara Obstoj-Cardwell. Editor

News early in last week was dominated by presentations at the American Society of Hematology (ASH) meeting. Among these was AstraZeneca, which released new data on the benefits of adding venetoclax to its Calquence in chronic leukemia. Also showing at ASH was Sino-American biotech BeiGene, which focused its presentations on Brukinsa in leukemia and lymphoma. On the regulatory front, shares of Dutch gene therapy uniQure leapt on news that it had agree a path forward for its Huntington’s candidate AMT-130. US biotech Q32 Bio released Ph IIA trial results for its bempikibart for alopecia areata that were described as “messy,” sending the firm’s shares plunging 75%. Keros Therapeutics was another big faller after the news that it was halting parts of its Phase II program with cibotercept in pulmonary hypertension.

AstraZeneca Monday ASH 2024 presentations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK